Keyword Connections

adalimumab

Journals

6

1 Frontiers in pharmacology

2 british journal of pharmacology

3 arthritis care & research

4 arthritis research & therapy

5 Journal of clinical immunology

6 journal of the european academy of dermatology and venereology : jeadv

Research Groups

0

No Research Group Connected

Bibliographies

29

1 Kyrle disease associated with hidradenitis suppurativa successfully treated with tumor necrosis factor inhibition.

2 Reply to The Letter to the Editors (ACR-19-1134) Opioid Use in Patients with Acute Gout.

3 Effectiveness of Adalimumab for the Treatment of Psoriatic Arthritis: An Italian Real-Life Retrospective Study.

4 Correction to: Management of adult-onset Still's disease with interleukin-1 inhibitors: evidence- and consensus-based statements by a panel of Italian experts.

5 Repositioning PARP inhibitors for SARS-CoV-2 infection (COVID-19); a new multi-pronged therapy for ARDS?

6 efficacy and safety of sarilumab in combination with csdmards or as monotherapy in subpopulations of patients with moderately to severely active rheumatoid arthritis in three phase iii randomized, controlled studies

7 a case of the secondary aa amyloidosis in bekhterev’s disease: a successful 3-year therapy with adalimumab

8 is adalimumab protective in ischemia-reperfusion injury in lung?

9 Complete Regression of Giant Inflammatory Polyp after Treatment with Adalimumab

10 Simultaneous Adalimumab and Antitubercular Treatment for Latent Tubercular Infection: An Experience from Nepal

11 A Case of Severe Symptomatic Central Nervous System Sarcoidosis Secondary to Treatment with Adalimumab

12 Successful Treatment of PAPA Syndrome with Dual Adalimumab and Tacrolimus Therapy.

13 Kurzfristige Wirksamkeit von Adalimumab bei einer Patientin mit pyrinassoziierter autoinflammatorischer Erkrankung mit neutrophiler Dermatose.

14 Relative efficacy and safety of tofacitinib, baricitinib, upadacitinib, and filgotinib in comparison to adalimumab in patients with active rheumatoid arthritis

15 Background Glucocorticoid Therapy Has No Impact on Efficacy and Safety of Abatacept or Adalimumab in Patients with Rheumatoid Arthritis

16 221 Development of abatacept- and adalimumab-specific predictive models of response to therapy in rheumatoid arthritis using data from a head-to-head study

17 221 Development of abatacept- and adalimumab-specific predictive models of response to therapy in rheumatoid arthritis using data from a head-to-head study

18 Background Glucocorticoid Therapy Has No Impact on Efficacy and Safety of Abatacept or Adalimumab in Patients with Rheumatoid Arthritis

19 adalimumab as a successful treatment for acne fulminans and bilateral acute sacroiliitis with hip synovitis complicating isotretinoin therapy

20 anti-tnf-alpha-adalimumab therapy is associated with persistent improvement of endothelial function without progression of carotid intima-media wall thickness in patients with rheumatoid arthritis refractory to conventional therapy

21 targeted treatment of psoriasis with adalimumab: a critical appraisal based on a systematic review of the literature

22 sustained maintenance of clinical remission after adalimumab dose reduction in patients with early psoriatic arthritis: a long-term follow-up study

23 critical appraisal of adalimumab in the treatment of chronic plaque psoriasis

24 bullous pemphigoid associated with adalimumab therapy in a patient with ulcerative colitis

25 antineutrophil cytoplasmic antibodies associated vasculitis in patient with crohn's disease treated with adalimumab

26 results of retrospective observational study of adalimumab safety and efficacy in patients with juvenile arthritis and uveitis

27 blockade of tumor necrosis factor-alpha: a role for adalimumab in neovascular age-related macular degeneration refractory to anti-angiogenesis therapy

28 Adalimumab induces deep remission in patients with Crohn's disease

29 Early clinical remission and normalisation of CRP are the strongest predictors of efficacy, mucosal healing and dose escalation during the first year of adalimumab therapy in Crohn's disease